Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and Durvalumab

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2024
The primary objective of this study is to compare the efficacy of tarlatamab plus durvalumab with durvalumab alone on prolonging overall survival (OS).
Epistemonikos ID: 110ae54cc39fe535e5b823ed79f814f9a8938872
First added on: May 15, 2024